In this analysis, we delve into the prospects of Aurizon Holdings (ASX:AZJ) and its anticipated performance in the upcoming fiscal years. While the company shows promising signs of robust EBITDA growth in FY24 and onwards, there are certain factors that might hinder its potential. Here, we examine the growth trajectory, dividend projections, and overall investment outlook for Aurizon Holdings.

Growth Projections

We anticipate Aurizon Holdings to exhibit significant EBITDA growth throughout FY24, with continued albeit slightly subdued growth in FY25-26. However, it's crucial to note that the potential escalation in debt service obligations might not be fully acknowledged in current market assessments.

Financial Outlook

Our analysis suggests a mid-teen compound growth in both earnings per share (EPS) and dividends per share (DPS) across FY24-26F. Notably, our forecast for FY26F dividends implies a noteworthy 7.1% cash yield at present prices, compared to 4.7% for FY24F. This signifies an attractive dividend proposition for investors considering Aurizon Holdings.

Investment Insights

Given the current market dynamics and our price target (accessible with login), we maintain a recommendation to HOLD Aurizon Holdings at current price levels. This stance is supported by the approximate 6% potential Total Shareholder Return (TSR) anticipated.

In conclusion, while Aurizon Holdings presents a solid growth narrative, it's essential for investors to consider the underlying factors, such as debt service obligations, before making investment decisions. With careful analysis and monitoring, Aurizon Holdings could still present an attractive investment opportunity despite the current pricing dynamics.

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.

News & Insights

To help you navigate this reporting season, our team of analysts have handpicked a list of key stocks in the Bank and Fund Manager space that are worth keeping an eye on.
Read full article
Inflation has been sticky and interest rates higher for longer than forecast. However, as rates come down and economic conditions improve, money is expected to continue to flow into the stock market and the emerging healthcare space.
Read full article
A strong result from Eli Lilly came amid a 2.3% surge in the S&P 500, the best day for the index since 2022. Eli Lilly raised sales and profit guidance for the year after a strong performance by its diabetes and weight loss drugs Mounjaro and Zepbound.
Read full article

News & Insights

Unlock the growth potential of Aurizon Holdings (ASX:AZJ). Explore projections, dividends, and investment insights in our latest analysis. Discover why Aurizon Holdings could be your next strategic investment.
Find out more